NEW YORK, NY / ACCESSWIRE / September 26, 2017 / U.S. markets dropped Monday as geopolitical tensions between the U.S. and North Korea grew and as technology stocks slumped. The Dow Jones Industrial Average declined 0.24 percent to close at 22,296.09, while the S&P 500 Index fell 0.22 percent to close at 2,496.66. The tech-heavy NASDAQ Composite Index fell 0.88 percent to close at 6,370.59. Apple Inc., which is the NASDAQ's largest component by market value, decline for the 4th consecutive session.

"Today is mostly about rotation from big-winning tech stocks and into losing energy and retail stocks, which is usually a healthy sign of the bull market," said Michael Antonelli, equity sales trader at Robert W. Baird & Co.

"As we have seen before, any news from North Korea have an instant impact on markets, but usually it does not last," Antonelli said.

RDI Initiates Coverage on:

Celldex Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CLDX

Genocea Biosciences Inc.
https://rdinvesting.com/news/?ticker=GNCA

Celldex Therapeutics Inc.'s stock jumped 12.97% on Monday, to close the day at $3.00. The stock recorded a trading volume of 5,059,036 shares, which was above its three months average volume of 1,286,630 shares. In the last year, Celldex Therapeutics Inc.'s shares have traded in a range of 2.20 - 5.02. The share price has gained 36.59% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.49 is below its 200-day moving average of $2.83. Shares of Celldex Therapeutics have fallen approximately 15.25 percent year-to-date.

Access RDI's Celldex Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLDX

On Monday, shares of Genocea Biosciences Inc. recorded a trading volume of 320,728 shares, which was below the three months average volume of 546,553 shares. The stock ended the day 0.38% higher at 5.31. The share price has gained 61.89% from its 52-week low with a 52-week trading range of 3.28 - 7.29.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $4.75 is below its 200-day moving average of $5.55. Shares of Genocea Biosciences have gained approximately 29.37 percent year-to-date.

Access RDI's Genocea Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GNCA

Our Actionable Research on Celldex Therapeutics Inc. (NASDAQ: CLDX) and Genocea Biosciences Inc. (NASDAQ: GNCA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com